July 8, 2020 / 1:30 PM / a month ago

BRIEF-Expres2ion Biotech Holding Updates On Negotiations With Bavarian Nordic

July 8 (Reuters) - ExpreS2ion Biotech Holding AB :

* EXPRES2ION PROVIDES UPDATE ON NEGOTIATIONS WITH BAVARIAN NORDIC AND PROGRESS TOWARDS CLINICAL PHASE I/IIA TRIAL

* ANNOUNCES THAT CVLP COVID-19 VACCINE LICENSE AGREEMENT NEGOTIATION BETWEEN ITS JOINT VENTURE ADAPTVAC AND BAVARIAN NORDIC IS EXPECTED TO CONTINUE BEYOND PREVIOUSLY ANNOUNCED TWO MONTHS’ TIME FRAME

* STILL EXPECTS VACCINE TO ENTER FIRST CLINICAL PHASE I/IIA SAFETY TRIAL BEFORE END OF 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below